1. Home
  2. TUYA vs ANAB Comparison

TUYA vs ANAB Comparison

Compare TUYA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tuya Inc. each representing one

TUYA

Tuya Inc. each representing one

HOLD

Current Price

$2.30

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$55.41

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TUYA
ANAB
Founded
2014
2005
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
TUYA
ANAB
Price
$2.30
$55.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
10
Target Price
$3.49
$62.20
AVG Volume (30 Days)
990.5K
421.9K
Earning Date
01-01-0001
04-06-2026
Dividend Yield
4.66%
N/A
EPS Growth
N/A
15.79
EPS
N/A
N/A
Revenue
N/A
$91,280,000.00
Revenue This Year
$8.84
$135.51
Revenue Next Year
$12.17
N/A
P/E Ratio
$27.45
N/A
Revenue Growth
N/A
432.03
52 Week Low
$1.87
$14.01
52 Week High
$4.17
$57.65

Technical Indicators

Market Signals
Indicator
TUYA
ANAB
Relative Strength Index (RSI) 65.79 64.38
Support Level $2.24 $43.67
Resistance Level $2.45 $57.65
Average True Range (ATR) 0.10 3.42
MACD 0.03 0.28
Stochastic Oscillator 98.81 86.46

Price Performance

Historical Comparison
TUYA
ANAB

About TUYA Tuya Inc. each representing one

Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers innovative physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It also provides a complete, open, and neutral global AIoT ecosystem. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: